SynAct Pharma AB (SE:SYNACT)
:SYNACT
Want to see SE:SYNACT full AI Analyst Report?
SYNACT Stock Chart & Stats
kr23.80
-kr0.24(-1.33%)
At close: 4:00 PM EST
kr23.80
-kr0.24(-1.33%)
Day’s Range― - ―
52-Week Rangekr13.40 - kr25.30
Previous CloseN/A
Volume43.49K
Average Volume (3M)214.83K
Market Cap
kr936.48M
Enterprise Valuekr884.88M
Total Cash (Recent Filing)kr68.89M
Total Debt (Recent Filing)kr1.54M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding53,330,242
10 Day Avg. Volume154,831
30 Day Avg. Volume214,829
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt-to-equity reduces near-term solvency risk and preserves strategic optionality. For a clinical-stage biotech this durable balance-sheet conservatism allows management to focus on R&D or negotiate partnerships without immediate refinancing pressure, supporting multi-month program continuity.
Oral Small-Molecule Lead CandidateResomelagon is an oral small-molecule melanocortin receptor agonist targeting inflammation resolution. Oral small molecules can offer durable advantages in development, manufacturing, patient adoption and cross-indication potential versus biologics, enhancing long-term commercial optionality if clinical data is supportive.
Clear Partnership/Out‑licensing PathwayAs a pre-revenue biotech, the company has a durable monetization pathway via out-licensing and partnerships. Strategic deals can fund late-stage development, provide non-dilutive milestones, and leverage larger pharma commercialization capabilities, reducing execution risk over ensuing months.
Bears Say
Heavy And Persistent Cash BurnSustained negative free cash flow near -97M in 2025 constrains runway and forces recurring financing or deal activity. Over a multi-month horizon this persistent burn elevates dilution risk, limits capacity to expand programs concurrently, and increases dependency on external capital or partnerships.
Pre‑Revenue With Widening LossesNo reported revenue combined with a widening net loss to ~111M in 2025 highlights the company's continued development-stage status. This structural lack of commercial cash flows raises execution and funding risk over months, and delays any margin improvement until successful commercialization or licensing.
Declining Shareholders' EquityA drop in equity from ~214M to ~170M signals accumulated losses and/or financing impacts, indicating mounting funding pressure. Durably, this trend increases the likelihood of future dilutive capital raises or less favorable partnership terms, compressing potential long-term shareholder returns.
SynAct Pharma AB News
SYNACT FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was kr13.40 and its highest was kr25.30 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is kr936.48M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is May 27, 2026 which is in 26 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on Feb 18, 2026. The company reported -kr0.43 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.43.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -kr0.43 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.407%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in SE:SYNACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---